

# Index

## A

Acute phase, 166, 187  
Acute poststroke inflammation, 168  
Agmatine, 101  
Alzheimer's disease, 31, 48  
Amyloid, 33, 152  
Anatomy, 1, 17  
Animal models, 95  
Anterior choroid artery, 27  
Anti-amyloid properties, 154  
Anti-apoptotic action, 156  
Anti-inflammatory action, 155  
Anti-inflammatory drugs, 98  
Antioxidant action, 155  
Anti-tau properties, 155  
Astrocytes, 77, 92  
Astrogliosis, 118

## B

B cells, 91  
Basal ganglia, 2  
Biomarkers, 51  
Blood brain barrier, 32, 166, 168  
Blood supply, 14, 27  
Borders, 3  
Brain infarction, 187  
Brain injury, 47, 51  
Brain ischemia, 32, 151  
Brainstem, 2

## C

CA1, 21, 33, 36  
CA3, 34, 36  
Cane, 194  
Caregivers, 195  
Case study, 205  
Cathepsin B, 131  
Cathepsins, 133  
Ceftriaxone, 100  
Central nervous system, 2  
Cerebral cortex, 1, 8  
Cerebral hemisphere, 1  
Cerebral infarction, 188  
Cerebral ischemia, 62, 111  
Cerebral ischemia-reperfusion injury, 64  
Cerebrum, 2  
Chronic phase, 173  
Cognitive impairment, 32  
Community-based rehabilitation, 187  
Connection of fornix, 18  
Cornu ammonis, 18  
Corpus callosum, 2  
Curcumin, 149  
Cytokines, 94

## D

Dementia, 32  
Dentate gyrus, 18, 19  
Dimensions of social risk, 204  
Disability as a social model, 204

**E**

Endolysosomal trafficking, 134  
Endothelial cells, 78  
Entorhinal cortex, 20  
Epigenetic mechanisms, 63  
Epigenetics, 157  
Escala de Valoracion Socio Familiar,  
205, 206  
Evaluating reintegration, 203  
Exosomes, 73  
Experimental stroke, 165  
Extracellular vesicles, 168

**F**

Fibrotic scar deposition, 116  
Fornix, 24  
Functional areas, 4, 10

**G**

Gasdermin D, 101  
Gender impact on social risk, 211  
Genes, 31  
Glial activators, 112  
Glial scar formation, 113  
Glial scarring, 118  
Glibenclamide, 99  
Grey matter, 2  
Guidance for family members, 195  
Gut-brain-axis, 172  
Gyri, 3

**H**

Habenular nuclei, 25  
Hippocampal formation, 18  
Hippocampus, 17, 32  
Histological structure, 8  
Homocysteine, 61, 63

Human ischemic stroke, 74  
Hyperhomocysteinemia, 61  
Hypoxic-ischemic brain injury, 45

**I**

Immobility syndromes, 191  
Immunological aspects, 170  
Immunomodulators, 98  
Immunosuppressants, 100  
Improvement of social risk categories, 211  
Indusium griseum, 19  
Inferior surface, 2  
Inflammation, 137  
Innate immune response, 116  
Interventricular foramen, 2  
Intracellular trafficking, 135  
Ischemia-reperfusion injury, 33, 131  
Ischemic brain injury, 61  
Ischemic preconditioning, 66

**J**

JAK2, 94  
JAK-STAT, 94  
Japan, 187  
JWH-133, 98

**K**

Keenest vision, 13  
Kinase, 78, 92  
Koniocortex, 9  
Koniocortical, 12, 10  
Koskinas classification, 10

**L**

Laminar organization, 9  
Lateral ventricle, 2  
Legal improvement, 196

Leukocytes, 89  
Limbic lobe, 18  
Lobes, 5  
Longitudinal striae, 19  
Long-term memory, 18  
Lower extremity orthoses, 193  
Lymphocytes, 89

## M

Macrophages, 89, 91  
Maintenance phase, 192  
Mammillo-tegmental tract, 25  
Mammillo-thalamic tract, 25  
Medial surface, 2  
Medial temporal cortex, 35  
Melatonin, 101  
Memory loss, 32  
Memory, 25  
Methionine metabolism, 61  
Microcirculation, 156  
Microglia, 77, 91  
Microglial activation, 116  
Micro-RNA, 75  
Microscopic structure, 21  
Modulation of tissue scar, 120  
Molecular pathways, 114  
Multicellular reactivity, 113

## N

Neurocan, 119  
Neurodegeneration, 31  
Neurogenesis, 156  
Neuroinflammation, 87, 96  
Neurological recovery, 120  
Neuronal circuit, 22  
Neuronal death, 137  
Neurons, 76  
Neuropathology, 32, 48, 151

Neuroprotective activity, 156  
Neuroprotective agents, 167  
Neuroregenerative approaches, 173  
Neurotoxicity, 63  
Neurovascular reactivity, 111  
Neutrophils, 89  
New memory, 26  
NMR metabolomic analysis, 64  
Novel therapeutic strategies, 165

## O

Oligodendrocytes, 78  
Orthoses, 194  
Orthotic therapy, 194

## P

Papez circuit, 22, 26  
Patient population cohort criteria, 205  
Perforant pathway, 23  
Pericytes, 112  
Perinatal asphyxia, 45  
Peripheral multi-organ injury, 50  
Phylogenetic classification, 10  
Phytotherapy, 102  
Poles, 2  
Post-asphyxia, 47  
Posterior cerebral artery, 27  
Post-ischemic brain, 31, 33, 73, 87, 89,  
91, 149  
Post-ischemic stroke patients, 201  
Poststroke delivery, 175  
Pyramidal cells, 21

## Q

Quality of life, 201, 202  
Questionnaires, 209

**R**

Reactive neurovascular unit cells, 116  
Recovery phase, 192  
Regulatory T cells, 90  
Rehabilitation hospitals and facilities, 196  
Rehabilitation, 187, 188  
Reintegration assessments, 203  
Reintegration, 201  
Robot therapy, 194

**S**

Sankey visualizations of risk variation, 209  
Sarnat grading scale, 51  
Scar-forming sources, 112  
Schaffer's collaterals, 23  
Short-term memory, 18  
Side effects, 158  
Social risk categories and risk factors, 209  
Social risk utilizing visualizations, 205  
Social risk variation, 201  
Sommer's sector, 26  
Spatial memory, 26  
Specialized social risk assessment, 205  
Statins, 100  
Stem cells, 101, 168  
Stroke severity impact on social risk, 215  
Stroke, 88, 131  
Subacute phase, 170  
Subiculum, 18  
Sulci, 3  
superolateral surface, 2  
Surfaces, 2  
Symptoms of disuse, 191

**T**

Tau protein, 36, 152

Telemedicine, 195  
Telerehabilitation, 195  
Telestroke, 195  
Tenascin-C, 119  
Therapy, 96  
Third ventricle, 2  
Tissue scarring, 111  
Transcription factors, 94  
Transplantation of stem cells, 173  
Treating cerebral ischemia, 165

**U**

UK-276, 98  
UK-279, 98  
Uncus, 4, 8  
Unmyelinated, 36

**V**

Vascular endothelial exosomes, 78  
Venous drainage, 27  
Visual cortex, 7  
Voluntary training, 195

**W**

Walking aids, 193  
Wernicke's speech areas, 12  
White matter, 2  
WY14643, 95

**Y**

Young people, 202

**Z**

Zingiberaceae, 150  
Zone, 7, 118